Investor Relations

We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Sonus Pharmaceuticals, Inc's financial performance into perspective.

Profile

Headquartered near Seattle, Washington, Sonus Pharmaceuticals, Inc. is focused on the development of cancer drugs that are designed to provide better efficacy, safety and tolerability, and are more convenient to use. Sonus moved SN2310, a novel camptothecin, into a Phase 1 clinical trial in September 2006.